126 related articles for article (PubMed ID: 36188616)
21. Clinical observation on the effect of Wuzhi soft capsule on FK506 concentration in membranous nephropathy patients.
Zhang Z; Lu X; Dong L; Ma J; Fan X
Medicine (Baltimore); 2019 Nov; 98(48):e18150. PubMed ID: 31770256
[TBL] [Abstract][Full Text] [Related]
22. Effects of Wuzhi Capsule on Whole-Blood Tacrolimus Concentration Levels: A Systematic Review and Meta-Analysis.
Zhang C; Ren X; Liu Y; Huang L; Feng Y; Zhang X
Ther Drug Monit; 2024 Feb; 46(1):33-41. PubMed ID: 38150711
[TBL] [Abstract][Full Text] [Related]
23. Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.
Chen X; Wang D; Xu H; Li Z
J Clin Pharm Ther; 2020 Apr; 45(2):309-317. PubMed ID: 31755126
[TBL] [Abstract][Full Text] [Related]
24. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.
Tang HL; Xie HG; Yao Y; Hu YF
Pharmacogenet Genomics; 2011 Nov; 21(11):713-20. PubMed ID: 21886016
[TBL] [Abstract][Full Text] [Related]
25. Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule.
Chen X; Wang DD; Xu H; Li ZP
Xenobiotica; 2020 May; 50(5):606-613. PubMed ID: 31530218
[TBL] [Abstract][Full Text] [Related]
26. Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.
Ghafari S; Dashti-Khavidaki S; Khatami MR; Ghahremani MH; Seyednejad SA; Beh-Pajooh A
Iran J Kidney Dis; 2019 Nov; 13(6):414-416. PubMed ID: 31880588
[TBL] [Abstract][Full Text] [Related]
27. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
Yanik MV; Seifert ME; Locke JE; Hauptfeld-Dolejsek V; Crowley MR; Cutter GR; Mannon RB; Feig DI; Limdi NA
Pediatr Transplant; 2019 Aug; 23(5):e13494. PubMed ID: 31124575
[TBL] [Abstract][Full Text] [Related]
28. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
Fukudo M; Yano I; Masuda S; Goto M; Uesugi M; Katsura T; Ogura Y; Oike F; Takada Y; Egawa H; Uemoto S; Inui K
Clin Pharmacol Ther; 2006 Oct; 80(4):331-45. PubMed ID: 17015051
[TBL] [Abstract][Full Text] [Related]
31. Wuzhi capsule increased systemic exposure to methotrexate by inhibiting the expression of OAT1/3 and P-gp.
Fu R; Wang XN; Guo CH; Li Y; Ding CY; Li YJ; Dong ZJ
Ann Transl Med; 2021 May; 9(10):845. PubMed ID: 34164479
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
[TBL] [Abstract][Full Text] [Related]
34. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
35. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
36. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients.
Largeau B; Guellec CB; Longuet H; Lesne P; Bouvarel A; Préteseille L; Marquet P; Halimi JM; Büchler M; Gatault P; Noble J
Prog Transplant; 2019 Dec; 29(4):300-308. PubMed ID: 31514576
[TBL] [Abstract][Full Text] [Related]
38. Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies.
Zong YP; Wang ZJ; Zhou WL; Zhou WM; Ma TL; Huang ZK; Zhao CC; Xu Z; Tan RY; Gu M
World J Pediatr; 2017 Oct; 13(5):421-426. PubMed ID: 28540692
[TBL] [Abstract][Full Text] [Related]
39. Effect of cytochrome P450 3A5 polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients.
Htun YY; Than NN; Swe HK
Korean J Transplant; 2020 Mar; 34(1):24-30. PubMed ID: 35770260
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients.
Du Y; Song W; Xiong X; Ge W; Zhu H
Xenobiotica; 2022 Mar; 52(3):274-283. PubMed ID: 35502774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
